(Q44119618)

30 November 2017

Iron chelation therapy with deferoxamine in Cooley anemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A633031

17 July 2022

0 references

1 reference

A. Cohen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A633031

17 July 2022

E. Schwartz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A633031

17 July 2022

language of work or name

English

0 references

publication date

1 April 1978

1 reference

full work available at URL

30 November 2017

https://api.elsevier.com/content/article/PII:S002234767880314X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(78)80314-X

https://api.elsevier.com/content/article/PII:S002234767880314X?httpAccept=text/plain

23 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(78)80314-X

The Journal of Pediatrics

23 August 2023

published in

1 reference

30 November 2017

92

1 reference

30 November 2017

4

1 reference

30 November 2017

643-647

1 reference

Management of thalassaemia major

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

LATE CARDIAC COMPLICATIONS OF CHRONIC, SEVERE, REFRACTORY ANEMIA WITH HEMOCHROMATOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Long-term desferrioxamine therapy in thalassemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Urinary iron excretion in thalassaemia after desferrioxamine administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Reassessment of the Use of Desferrioxamine B in Iron Overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

The Effect of Ascorbic Acid Deficiency on Desferrioxamine-Induced Urinary Iron Excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Measurement of serum ferritin by a 2-site immunoradiometric assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2878%2980314-X

Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload

7 January 2021

series ordinal

9

1 reference

https://api.crossref.org/works/10.1016/S0022-3476(78)80314-X

23 August 2023

Identifiers

1 reference

30 November 2017

1 reference